Heritas Capital
Heritas hits $20m first close on Asia impact fund
Singapore-based private equity firm Heritas Capital has reached a first close of USD 20m on its latest Asia impact fund against an overall target of USD 50m. DBS contributed USD 10m.
Deal focus: Singapore biotech start-up generates US buzz
Singapore’s Tessa Therapeutics has developed a cancer drug that appears to be twice as effective as other treatments in its class. It has raised USD 126m with eyes on a near-term US IPO
Singapore cancer treatment start-up gets $126m Series A
Singapore’s Tessa Therapeutics, a biotech developer with a Hodgkin's lymphoma treatment in phase-two trials, has raised a USD 126m Series A round led by US healthcare specialist Polaris Partners.
China's Bits x Bites closes second food tech fund at $100m
Bits x Bites, a Chinese VC firm focused on agriculture and food technology such as alternative protein, has closed its second fund at $100 million, beating a target of $70 million.